



VGYAAN Pharmaceuticals Receives US FDA Approval for Ursodiol Capsules USP, Generic Equivalent to ACTIGALL®

July 28, 2021

Skillman, NJ -- VGYAAN Pharmaceuticals today announced that it has received final US FDA approval for Ursodiol Capsules USP 300 mg, the generic equivalent to ACTIGALL®.

Ursodiol is indicated for patients with radiolucent noncalcified gallbladder stones, and for the prevention of gallstone formation in obese patients experiencing rapid weight loss.

Nailesh Bhatt, Chief Executive Officer of VGYAAN Pharmaceuticals commented, “With this latest approval, VGYAAN now has three drugs approved by the FDA. In addition, we have multiple product applications with the FDA awaiting approvals in our quest to provide high quality, affordable generic drugs to patients. We look forward to working with our valuable customers and channel partners to launch Ursodiol in the near future.”

About VGYAAN Pharmaceuticals

VGYAAN Pharmaceuticals LLC, headquartered in Skillman, New Jersey is focused on developing and commercializing clinically critical drugs. VGYAAN is fully equipped and licensed to perform sales, marketing, and distribution of high quality and affordable drugs in the US with capabilities to serve clients across a wide range of channels. Our product portfolio includes solid orals and injectables in a broad range of therapeutic areas.

For more information, please visit www.vgyaan.com or contact media@vgyaan.com.

ACTIGALL® is a registered trademark of Allergan Sales, LLC.